Big Pharma is out with encouraging cancer-survival data and response rates prior to the June ASCO event.
The biotech launches Cabometyx for kidney cancer.
Bristol-Myers' shares touched a 17-year high in April -- can the good times continue?
First quarter earnings could impact trading in this big cap pharmaceutical stock. Here's what you need to know.
Nike, Microsoft, and Bristol-Myers Squibb could be worth owning in any investor's portfolio.
Former partners are set to battle it out in the marketplace.
Here are a few good reasons why ExxonMobil, Bristol-Myers Squibb, and Microsoft would make smart additions to conservative income hunters' portfolios.
ExxonMobil, AT&T, Deere & Co, Bristol-Myers Squibb, and Microsoft all offer compelling dividend yields that could boost income in retirement.
Runaway drug spending is costing Americans billions of dollars every year.
Updated results for its clinical-stage hepatitis C drug failed to spark a rally.